Research Article

Department of Urology & Andrology, Minimally Invasive Surgery Center, Guangdong Provincial Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510000, PR China

Search for more papers by this author

Han Lin

Department of Gynecology of Traditional Chinese Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510000, PR China

Search for more papers by this author

Mingda Zhou

Search for more papers by this author

Qian Xiang

Search for more papers by this author

Yihan Deng

Search for more papers by this author

Lianmin Luo

Search for more papers by this author

Yangzhou Liu

Search for more papers by this author

Zhiguo Zhu

Search for more papers by this author

Zhigang Zhao

*Author for correspondence: Tel.: +86 20 3429 5590;

E-mail Address: zgzhaodr@126.com

https://orcid.org/0000-0003-3147-8544

Search for more papers by this author

Published Online:20 Jul 2020https://doi.org/10.2217/fon-2020-0330

View article

Abstract

Aim: To construct a survival prediction signature for prostate cancer (PC) based on the RNA N6-methyladenosine (m6A) methylation regulator. Materials & methods: This paper explores the interaction network of differentially expressed m6A RNA methylation regulators in PC by Pearson correlation analysis. Univariate Cox risk regression and LASSO regression analysis were used to construct a predictive signature of PC. Kaplan–Meier survival analysis compared the overall survival of the high- and low-risk groups. Results & Conclusion: We first constructed a prognostic two gene signature for PC based on the m6A RNA methylation regulators MRTTL14 and YTHDF2. The interaction network of m6A RNA methylation regulators in PC was also established.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J. Clin. 68(1), 7–30 (2018).
MedlineGoogle Scholar
2. Center MM, Jemal A, Lortet-Tieulent J et al. International variation in prostate cancer incidence and mortality rates. Eur. Urol. 61(6), 1079–1092 (2012).
MedlineGoogle Scholar
3. Kakehi Y, Sugimoto M, Taoka R. Evidenced-based clinical practice guideline for prostate cancer (summary: Japanese Urological Association, 2016 edition). Int. J. Urol. 24(9), 648–666 (2017).
MedlineGoogle Scholar
4. Miller KD, Siegel RL, Lin CC et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J. Clin. 66(4), 271–289 (2016).
MedlineGoogle Scholar
5. Stattin P, Vickers AJ, Sjoberg DD et al. Improving the specificity of screening for lethal prostate cancer using prostate-specific antigen and a panel of Kallikrein markers: a nested case-control study. Eur. Urol. 68(2), 207–213 (2015).
Medline CASGoogle Scholar
6. Greene KL, Albertsen PC, Babaian RJ et al. Prostate specific antigen best practice statement: 2009 update. J. Urol. 189(Suppl. 1), S2–S11 (2013).
MedlineGoogle Scholar
7. Boutros PC, Fraser M, Harding NJ et al. Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nat. Genet. 47(7), 736–745 (2015).
Medline CASGoogle Scholar
8. Tolkach Y, Kristiansen G. The heterogeneity of prostate cancer: a practical approach. Pathobiology 85(1–2), 108–116 (2018).
Medline CASGoogle Scholar
9. Muntean AG, Hess JL. Epigenetic dysregulation in cancer. Am. J. Pathol. 175(4), 1353–1361 (2009).
Medline CASGoogle Scholar
10. Liu N, Pan T. N6-methyladenosine-encoded epitranscriptomics. Nat. Struct. Mol. Biol. 23(2), 98–102 (2016).
Medline CASGoogle Scholar
11. Davalos V, Blanco S, Esteller M. SnapShot: messenger RNA modifications. Cell 174(2), 498 (2018).
Medline CASGoogle Scholar
12. Jantsch MF, Quattrone A, O'Connell M et al. Positioning Europe for the EPITRANSCRIPTOMICS challenge. RNA Biol. 15(6), 829–831 (2018).
MedlineGoogle Scholar
13. Yue Y, Liu J, He C. RNA N6-methyladenosine methylation in post-transcriptional gene expression regulation. Genes Dev. 29(13), 1343–1355 (2015).
Medline CASGoogle Scholar
14. Chen XY, Zhang J, Zhu JS. The role of m(6)A RNA methylation in human cancer. Mol. Cancer 18(1), 103 (2019). •• Summarized the N6-methyladenosine (m6A) RNA methylation regulators and illustrated the corresponding mechanism, which is very helpful to understand the mechanism of m6A.
MedlineGoogle Scholar
15. Fustin JM, Doi M, Yamaguchi Y et al. RNA-methylation-dependent RNA processing controls the speed of the circadian clock. Cell 155(4), 793–806 (2013).
Medline CASGoogle Scholar
16. Mendel M, Chen KM, Homolka D et al. Methylation of structured RNA by the m(6)A writer METTL16 is essential for mouse embryonic development. Mol. Cell 71(6), 986–1000 (2018).
Medline CASGoogle Scholar
17. Lence T, Akhtar J, Bayer M et al. m(6)A modulates neuronal functions and sex determination in Drosophila. Nature 540(7632), 242–247 (2016).
Medline CASGoogle Scholar
18. Du K, Zhang L, Lee T, Sun T. m(6)A RNA methylation controls neural development and is involved in human diseases. Mol. Neurobiol. 56(3), 1596–1606 (2019).
Medline CASGoogle Scholar
19. Wang CY, Yeh JK, Shie SS, Hsieh IC, Wen MS. Circadian rhythm of RNA N6-methyladenosine and the role of cryptochrome. Biochem. Biophys. Res. Commun. 465(1), 88–94 (2015).
Medline CASGoogle Scholar
20. Zhou J, Wan J, Shu XE et al. N(6)-methyladenosine guides mRNA alternative translation during integrated stress response. Mol. Cell 69(4), 636–647 (2018).
Medline CASGoogle Scholar
21. Yang Y, Hsu PJ, Chen YS, Yang YG. Dynamic transcriptomic m(6)A decoration: writers, erasers, readers and functions in RNA metabolism. Cell Res. 28(6), 616–624 (2018).
Medline CASGoogle Scholar
22. Lian H, Wang QH, Zhu CB, Ma J, Jin WL. Deciphering the epitranscriptome in cancer. Trends Cancer 4(3), 207–221 (2018).
Medline CASGoogle Scholar
23. Esteller M, Pandolfi PP. The epitranscriptome of noncoding RNAs in cancer. Cancer Discov. 7(4), 359–368 (2017).
Medline CASGoogle Scholar
24. Zhang S. Mechanism of N(6)-methyladenosine modification and its emerging role in cancer. Pharmacol. Ther. 189, 173–183 (2018). • Summarized the post-transcriptional modification of m6A to a certain extent, which is helpful to understand how m6A plays a role in tumors.
Medline CASGoogle Scholar
25. Tusup M, Kundig T, Pascolo S. Epitranscriptomics of cancer. World J. Clin. Oncol. 9(3), 42–55 (2018). • Summarized the post-transcriptional modification of m6A to a certain extent, which is helpful to understand how m6A plays a role in tumors.
MedlineGoogle Scholar
26. Wang S, Chai P, Jia R, Jia R. Novel insights on m(6)A RNA methylation in tumorigenesis: a double-edged sword. Mol. Cancer 17(1), 101 (2018).
MedlineGoogle Scholar
27. Cai J, Yang F, Zhan H et al. RNA m(6)A methyltransferase METTL3 promotes the growth of prostate cancer by regulating Hedgehog pathway. Onco Targets Ther. 12, 9143–9152 (2019). • There is a dearth of research on m6A in prostate cancer. The authors found that METTL3 could promotes the growth of prostate cancer by regulating the Hedgehog pathway.
Medline CASGoogle Scholar
28. He L, Li H, Wu A, Peng Y, Shu G, Yin G. Functions of N6-methyladenosine and its role in cancer. Mol. Cancer 18(1), 176 (2019).
MedlineGoogle Scholar
29. Shi H, Wei J, He C. Where, when, and how: context-dependent functions of RNA methylation writers, readers, and erasers. Mol. Cell 74(4), 640–650 (2019).
Medline CASGoogle Scholar
30. Liu J, Harada BT, He C. Regulation of gene expression by N(6)-methyladenosine in cancer. Trends Cell. Biol. 29(6), 487–499 (2019).
MedlineGoogle Scholar
31. Roundtree IA, Evans ME, Pan T, He C. Dynamic RNA modifications in gene expression regulation. Cell 169(7), 1187–1200 (2017).
Medline CASGoogle Scholar
32. Fedeles BI, Singh V, Delaney JC, Li D, Essigmann JM. The AlkB family of Fe(II)/alpha-ketoglutarate-dependent dioxygenases: repairing nucleic acid alkylation damage and beyond. J. Biol. Chem. 290(34), 20734–20742 (2015).
Medline CASGoogle Scholar
33. Yang F, Jin H, Que B et al. Dynamic m(6)A mRNA methylation reveals the role of METTL3-m(6)A-CDCP1 signaling axis in chemical carcinogenesis. Oncogene 38(24), 4755–4772 (2019).
Medline CASGoogle Scholar
34. Cheng M, Sheng L, Gao Q et al. The m(6)A methyltransferase METTL3 promotes bladder cancer progression via AFF4/NF-kappaB/MYC signaling network. Oncogene 38(19), 3667–3680 (2019).
Medline CASGoogle Scholar
35. Shi LP, Liang M, Li FF et al. MiR-492 exerts tumor-promoting function in prostate cancer through repressing SOCS2 expression. Eur. Rev. Med. Pharmacol. Sci. 23(3), 992–1001 (2019).
MedlineGoogle Scholar
36. Miyamoto A, Masuhiro Y, Seki T, Hanazawa S, Shiba H. A designed cell-penetrating human SOCS2 protein suppresses GH-dependent cancer cell proliferation. Biosci. Biotechnol. Biochem. 83(2), 300–308 (2019).
Medline CASGoogle Scholar
37. Liu J, Eckert MA, Harada BT et al. m(6)A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat. Cell Biol. 20(9), 1074–1083 (2018).
Medline CASGoogle Scholar
38. Niu Y, Lin Z, Wan A et al. RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3. Mol. Cancer 18(1), 46 (2019).
MedlineGoogle Scholar
39. Zhao Y, Tao Z, Chen X. Identification of a three-m6A related gene risk score model as a potential prognostic biomarker in clear cell renal cell carcinoma. PeerJ 8, e8827 (2020).
MedlineGoogle Scholar
40. Du J, Hou K, Mi S et al. Malignant evaluation and clinical prognostic values of m6A RNA methylation regulators in glioblastoma. Front. Oncol. 10, 208 (2020).
MedlineGoogle Scholar
41. Chen M, Nie ZY, Wen XH, Gao YH, Cao H, Zhang SF. m6A RNA methylation regulators can contribute to malignant progression and impact the prognosis of bladder cancer. Biosci. Rep. 39(12), (2019).
Google Scholar
42. Zhao X, Cui L. Development and validation of a m(6)A RNA methylation regulators-based signature for predicting the prognosis of head and neck squamous cell carcinoma. Am. J. Cancer Res. 9(10), 2156–2169 (2019).
Medline CASGoogle Scholar
43. Wang P, Doxtader KA, Nam Y. Structural basis for cooperative function of Mettl3 and Mettl14 methyltransferases. Mol. Cell 63(2), 306–317 (2016).
Medline CASGoogle Scholar
44. Wang X, Feng J, Xue Y et al. Structural basis of N(6)-adenosine methylation by the METTL3–METTL14 complex. Nature 534(7608), 575–578 (2016).
Medline CASGoogle Scholar
45. Vu LP, Pickering BF, Cheng Y et al. The N(6)-methyladenosine (m(6)A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. Nat. Med. 23(11), 1369–1376 (2017).
Medline CASGoogle Scholar
46. Barbieri I, Tzelepis K, Pandolfini L et al. Promoter-bound METTL3 maintains myeloid leukaemia by m(6)A-dependent translation control. Nature 552(7683), 126–131 (2017).
Medline CASGoogle Scholar
47. Weng H, Huang H, Wu H et al. METTL14 inhibits hematopoietic stem/progenitor differentiation and promotes leukemogenesis via mRNA m(6)A modification. Cell Stem Cell 22(2), 191–205 (2018).
Medline CASGoogle Scholar
48. Ma JZ, Yang F, Zhou CC et al. METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N(6)-methyladenosine-dependent primary MicroRNA processing. Hepatology 65(2), 529–543 (2017).
Medline CASGoogle Scholar
49. Gu C, Wang Z, Zhou N et al. Mettl14 inhibits bladder TIC self-renewal and bladder tumorigenesis through N(6)-methyladenosine of Notch1. Mol. Cancer 18(1), 168 (2019).
Medline CASGoogle Scholar
50. Yang X, Zhang S, He C et al. METTL14 suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XIST. Mol. Cancer 19(1), 46 (2020).
Medline CASGoogle Scholar
51. Wang X, Lu Z, Gomez A et al. N6-methyladenosine-dependent regulation of messenger RNA stability. Nature 505(7481), 117–120 (2014).
MedlineGoogle Scholar
52. Paris J, Morgan M, Campos J et al. Targeting the RNA m(6)A reader YTHDF2 selectively compromises cancer stem cells in acute myeloid leukemia. Cell Stem Cell 25(1), 137–148 (2019).
Medline CASGoogle Scholar
53. Li Z, Qian P, Shao W et al. Suppression of m(6)A reader Ythdf2 promotes hematopoietic stem cell expansion. Cell Res. 28(9), 904–917 (2018).
Medline CASGoogle Scholar
54. Chen M, Wei L, Law CT et al. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. Hepatology 67(6), 2254–2270 (2018).
Medline CASGoogle Scholar
55. Xie H, Li J, Ying Y et al. METTL3/YTHDF2 m(6) A axis promotes tumorigenesis by degrading SETD7 and KLF4 mRNAs in bladder cancer. J. Cell. Mol. Med. 24(7), 4092–4104 (2020).
Medline CASGoogle Scholar
56. Zhong L, Liao D, Zhang M et al. YTHDF2 suppresses cell proliferation and growth via destabilizing the EGFR mRNA in hepatocellular carcinoma. Cancer Lett. 442, 252–261 (2019).
Medline CASGoogle Scholar

Vol. 16, No. 30

Metrics

Downloaded 336 times

History

Received 11 April 2020

Accepted 24 June 2020

Published online 20 July 2020

Published in print October 2020

Information

Keywords

Author contributions

J Wang, H Lin and M Zhou have contributed equally to this work.

Financial & competing interests disclosure

This work was supported by the grants from Science and technology innovation project for college students of Guangzhou Medical University (no. 2019A003 for J Wang). This work was supported by the grants from National Natural Science Foundation of China (nos. 81372774, 81572537 for Z Zhao), The Key Program of Natural Science Foundation of Guangdong Province (no. 2015A030311007 for Z Zhao), Science and Technology Program of Guangzhou (no. 201607010376 for Z Zhao) and The Major Program of Department of Guangdong Education (no. 2017KZDXM067 for Z Zhao). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that for investigations involving human subjects, informed consent has been obtained from the participants involved.

Data availability

The RNA-seq transcriptome data of PC and normal tissues were obtained from the TCGA public database (https://portal.gdc.cancer.gov/). Therefore, no ethical approval is required.

PDF download

The m6A methylation regulator-based signature for predicting the prognosis of prostate cancer

Abstract

References